Global Protein Therapeutics Market Dominated by Monoclonal Antibodies
According to the market research report "Global Protein Therapeutics Market Analysis", the Protein Therapeutic Market was valued in excess of US$ 57 Billion in 2006 and according to projections, it would grow at a CAGR 12.83% till 2010 The market is presently dominated by monoclonal antibodies and with double-digit growth projected for future, the segment is expected to bolster its dominant position. insulin, Interferon Beta, G-CSF and coagulation factors are also exhibiting double-digit growth rates.
One of the biggest opportunity areas in the Protein Therapeutics Market will be in the field of Biogenerics, which is expected to create a multi-billion dollar market in future.
The key findings of the market report include:
- US is the largest market for therapeutic proteins in the world followed by Europe and Japan.
- Insurance reimbursement is a major factor that decides the success of protein therapeutics.
- Growth in protein therapeutic market will create new opportunities for the drug discovery Contract Research Organizations (CROs).
- High expenditure on R&D and high rate of failure in phase-3 clinical trials remains a major challenge for the global protein therapeutics market.
- Until recently, protein therapeutics faced little generic threat; however, this is likely to change in future with regulatory pathways for the approval of generics already present in Europe and Asia and to be introduced in US by 2009.
Most read news
Topics
Organizations
Related link
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous